Disciplined Growth Investors Inc. MN lowered its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 1.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,348,107 shares of the company’s stock after selling 13,425 shares during the quarter. Disciplined Growth Investors Inc. MN owned about 1.95% of Myriad Genetics worth $48,775,000 at the end of the most recent quarter.
A number of other institutional investors also recently made changes to their positions in MYGN. Teachers Advisors LLC lifted its holdings in shares of Myriad Genetics by 1.1% during the first quarter. Teachers Advisors LLC now owns 116,924 shares of the company’s stock worth $2,245,000 after buying an additional 1,287 shares during the last quarter. Aperio Group LLC lifted its holdings in shares of Myriad Genetics by 4.6% during the second quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock worth $313,000 after buying an additional 534 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its holdings in shares of Myriad Genetics by 3.1% during the second quarter. Municipal Employees Retirement System of Michigan now owns 16,080 shares of the company’s stock worth $416,000 after buying an additional 490 shares during the last quarter. Great West Life Assurance Co. Can lifted its holdings in shares of Myriad Genetics by 3.3% during the second quarter. Great West Life Assurance Co. Can now owns 100,694 shares of the company’s stock worth $2,598,000 after buying an additional 3,180 shares during the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of Myriad Genetics during the second quarter worth approximately $218,000.
Myriad Genetics, Inc. (MYGN) opened at $33.74 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The company has a market capitalization of $2,336.19, a price-to-earnings ratio of 30.95, a P/E/G ratio of 2.14 and a beta of 0.25. Myriad Genetics, Inc. has a 12 month low of $15.15 and a 12 month high of $37.30.
Myriad Genetics (NASDAQ:MYGN) last issued its earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.05. The business had revenue of $190.20 million during the quarter, compared to analyst estimates of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. Myriad Genetics’s revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share. research analysts predict that Myriad Genetics, Inc. will post 1.05 EPS for the current fiscal year.
A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price target for the company in a report on Tuesday, October 17th. Cowen reiterated a “hold” rating and set a $25.00 price target on shares of Myriad Genetics in a report on Sunday, September 17th. Deutsche Bank upgraded Myriad Genetics from a “sell” rating to a “hold” rating and cut their price target for the stock from $27.86 to $15.00 in a report on Friday, August 18th. Morgan Stanley reiterated an “underweight” rating and set a $24.00 price target (up from $17.00) on shares of Myriad Genetics in a report on Friday, October 6th. Finally, Stephens reiterated an “overweight” rating and set a $40.00 price target (up from $36.00) on shares of Myriad Genetics in a report on Friday, September 22nd. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $28.10.
In related news, insider Alexander Ford sold 3,031 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.70% of the company’s stock.
WARNING: “Myriad Genetics, Inc. (MYGN) Holdings Cut by Disciplined Growth Investors Inc. MN” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2017/12/11/myriad-genetics-inc-mygn-holdings-cut-by-disciplined-growth-investors-inc-mn.html.
Myriad Genetics Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.